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Abstract
Appropriate adjuvant selection may be essential to optimize the potency and to tailor the
immune response of subunit vaccines. To induce protective responses against respiratory
syncytial virus (RSV)—a highly prevalent childhood pathogen without a licensed vaccine—
we previously engineered a pre-fusion-stabilized trimeric RSV F (pre-F) “DS-Cav1” immuno-
gen, which induced high titer RSV-neutralizing antibodies, in mice and non-human primates,
when formulated with adjuvants Poly (I:C) and Poly (IC:LC), respectively. To assess the
impact of different adjuvants, here we formulated RSV F DS-Cav1 with multiple adjuvants
and assessed immune responses. Very high RSV-neutralizing antibody responses (19,006
EC50) were observed in naïve mice immunized with 2 doses of DS-Cav1 adjuvanted with
Sigma adjuvant system (SAS), an oil-in-water adjuvant, plus Carbopol; high responses
(3658–7108) were observed with DS-Cav1 adjuvanted with Alum, SAS alone, Adjuplex,
Poly (I:C) and Poly (IC:LC); and moderate responses (1251–2129) were observed with DS-
Cav1 adjuvanted with the TLR4 agonist MPLA, Alum plus MPLA or AddaVax. In contrast,
DS-Cav1 without adjuvant induced low-level responses (6). A balanced IgG1 and IgG2a
(Th2/Th1) immune response was elicited in most of the high to very high response groups
(all but Alum and Adjuplex). We also tested the immune response induced by DS-Cav1 in
elderly mice with pre-existing DS-Cav1 immunity; we observed that DS-Cav1 adjuvanted
with SAS plus Carbopol boosted the response 2-3-fold, whereas DS-Cav1 adjuvanted with
alum boosted the response 5-fold. Finally, we tested whether a mixture of ISA 71 VG and
Carbopol would enhanced the antibody response in DS-Cav1 immunized calves. While pre-
F-stabilized bovine RSV F induced very high titers in mice when adjuvanted with SAS plus
Carbopol, the addition of Carbopol to ISA 71 VG did not enhance immune responses in
calves. The vaccine response to pre-F-stabilized RSV F is augmented by adjuvant, but the
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degree of adjuvant-induced enhancement appears to be both context-dependent and spe-
cies-specific.
Introduction
Human respiratory syncytial virus (RSV) infection is the most common cause of hospitaliza-
tion for lower respiratory tract infection (LTRI) in children under five years of age, worldwide.
Severe RSV disease occurs at the extremes of age. RSV is the leading cause of death due to
LTRI in children under six months of age [1]. Among elderly patients, RSV infection is also a
major cause of hospitalizations and associated deaths in the USA [2–4]. Thus, the development
of an effective RSV vaccine is of substantial importance. Live vaccines such as the smallpox
vaccine pioneered by Jenner [5] provide immunity, but may have safety risks; inactivated vac-
cines are generally safer, but when a formalin-inactivated RSV vaccine adjuvanted with alum
was evaluated in healthy infants and young children in the 1960’s [6, 7] 80% of vaccinees who
were infected required hospitalization compared to 5% of the control group.
Considerable effort has been directed towards developing subunit -based RSV vaccines
designed to elicit potently neutralizing antibodies targeting specific epitopes. RSV F and G sur-
face proteins as well as chimeric F/G variants when used as immunogens, resulted in robust
albeit poorly neutralizing antibodies [8, 9]. These subunit vaccine approaches have been fur-
ther explored in both purified protein [10–13] and vector-based formats [14, 15]. Vaccine
approaches based on soluble proteins are generally poorly immunogenic and usually require
adjuvants to augment their immunogenicity. A number of synthetic and natural compounds
have been identified to have adjuvant activity, however, only a few including alum, squalene
oil-in-water (MF59), and monophosphoryl lipid A (MPLA) have achieved widespread human
use. Most adjuvants either activate pattern recognition receptors (PRRs, such as toll-like recep-
tors (TLRs)) in the innate immune system or improve the delivery of antigens to the immune
system. The most common adjuvant, alum, comprised of aluminum salts, has been used in
humans since 1932, is approved for human use by the FDA, and is a component of numerous
licensed vaccines such as Diphtheria, Tetanus and Pertussis (DTaP) vaccines, and hepatitis B
vaccines. MPLA with Alum is used for the hepatitis B vaccine, Fendrix, and the human papillo-
mavirus (HPV) vaccine, Cervarix, and has extensive human safety data in this context. Oil-in-
water formulations such as MF59 [16] are components of FLUAD (a new seasonal flu vaccine
for the elderly) MPLA is also a component of Pollinex Quattro, a vaccine used for the treat-
ment of seasonal allergic rhinitis [17]. Combinations of MF59 with polyanionic carbomers
[16, 18] as well as Adjuplex (a coformulation of carbomer with lecithin [19]) are potent and
well-tolerated adjuvants when administered with subunit vaccines. Carbomers have also been
evaluated as experimental adjuvants in veterinary vaccines against swine parvovirus [20], cir-
covirus type 2 [21], Staphylococcus aureus in sheep [22], and equine influenza virus [23]. Poly
(I:C), a synthetic double-stranded RNA and its derivative Poly (IC:LC) [10, 24] have been
reported in a range of animal species from mice to nonhuman primates revealing significant
enhancement of immunogenicity and are in cancer immunotherapy clinical trials [25] and are
a component of intranasal flu vaccine FluMist [26]. Montanide is a family of oil-based adju-
vants used to produce an emulsion with the antigen of interest. It has been used in experimen-
tal vaccines in mice, rats, dogs and cats using natural, recombinant and synthetic antigens.
Montanide is used worldwide in both bovine and ovine vaccinations against viral, bacterial or
parasitic diseases. In humans, Montanide emulsions have been used in experimental human
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vaccines against HIV, malaria and breast cancer [27, 28]. Each of these adjuvants have unique
characteristics and mechanisms, and their impact on the immune response induced by a par-
ticular immunogen generally needs to be determined experimentally.
We previously engineered a pre-fusion stabilized trimeric RSV F (pre-F) immunogen,
named “DS-Cav1”. DS-Cav1 when adjuvanted with TLR3 agonists Poly (I:C) and Poly (IC:LC)
induces high neutralizing antibody titers in mice and nonhuman primates, respectively [10].
Herein, we report a comparative adjuvant study with DS-Cav1 formulated with nine different
adjuvants (Table 1) in naïve mice. We also studied elderly mice that had been pre-immunized
with DS-Cav1 adjuvanted with Poly (I:C). We further evaluated the impact of Carbopol in
mice and calves using a bovine RSV F version of DS-Cav1. The results indicate that adjuvant is
required for DS-Cav1 to induce high titer responses, that moderate to high titer responses can
be induced by all the adjuvants tested, and that the optimal response to adjuvants appears to
be both context-dependent (e.g. whether animals have pre-existing responses) and species-spe-
cific (e.g. the addition of Carbopol induced very high responses in mice, but not in calves).
Materials and methods
Adjuvants
Alhydrogel (Alum) was purchased from Brenntag, Denmark, AddaVax, Monophosphoryl
Lipid A-SM (MPLA) and Poly (I:C) were purchased from Invivogen, Sigma Adjuvant System
(SAS) and Adjuplex were purchased from Sigma-Aldrich, Carbopol was a gift from Mutchler
Inc, Poly (IC:LC) was a gift from A.M. Salazar, Oncovir, DC. Montanide ISA 71 VG was a gift
from Seppic, France.
Cell lines, resins and proteases
Expi293F cells and 293fectin were purchased from Thermo Fisher scientific, Ni Sepharose
Excel and Strep-Tactin Superflow resins were purchased from GE Healthcare and IBA, respec-
tively. Restriction grade thrombin was obtained from Novagen. HEp2 cells were purchased
from ATCC, VA.
Table 1. Adjuvants and their proposed mode of action.
Adjuvant Characteristics Putative mechanism, receptor, type of immune
response
Aluminium salts (Aluminium
hydroxide)
Gel suspension Inflammasome activation; Th2 biased response
[29],[30]
Poly (I:C) dsRNA (Inosine, cytidine homologue) TLR3 Agonist (immunomodulatory molecule) [31]
Poly (IC:LC) dsRNA (Complex of carboxymethylcellulose, polyinosinic-
polycytidylic, and poly-L-lysine double-stranded RNA)
TLR3 Agonist (immunomodulatory molecule) [24]
Monophosphoryl Lipid A-SM Phospholipid Surface PRR activation; TLR4 agonist,
Immunomodulatory molecule [32] [33, 34].
Sigma Adjuvant System
(SAS)
Oil-in-water emulsion, MPLA and trehalose dicorynomycolate Enhanced antigen uptake; TLR4 agonist
MPLA + Alum Phospholipid plus gel suspension TLR4 agonist, combination
SAS + Carbopol Oil-in-water emulsion, MPLA, trehalose dicorynomycolate.
Polyanionic high mol. weight acrylic acid
TLR4 agonist and controlled release of antigen[21]
Adjuplex Lecithin & Carbomer (cross-linked polyacrylic acid) homopolymer Th1/Th2 balanced response [19]
AddaVax Squalene based Oil in Water Emulsion Th1/Th2 balanced response[35]
MontanideTM ISA 71 VG Water in oil emulsion Th1/Th2 balanced response
MontanideTM ISA 71 VG
+ Carbopol
Water in oil emulsion. Polyanionic high mol. weight acrylic acid Th1/Th2 balanced response and controlled release
of antigen
https://doi.org/10.1371/journal.pone.0186854.t001
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Protein expression and purification
RSV F DS-Cav1 [10] and RSV F DS-Cav1 site Ø (K65N-N67T, P205N-V207T, K209N-S211T)
and site II (N268R-K272E) knock-out (KO) proteins were expressed by transient transfection of
Expi293F cells using 293fectin. The culture supernatant was harvested 5 days post transfection
and centrifuged at 10,000 g to remove cell debris. The supernatant was sterile-filtered and RSV
F DS-Cav1 was purified by Nickel and Strep-Tactin-affinity chromatography followed by size-
exclusion chromatography using a Superdex 200 16/60 column (GE Healthcare). The His8 and
Strep-Tactin purification tags were removed from the RSV F protein by digestion with restric-
tion-grade biotinylated thrombin (Novagen) overnight at 4˚C. Cleaved RSV F DS-Cav1 was fur-
ther purified by size-exclusion chromatography (SEC) in phosphate-buffered saline (PBS) prior
to immunization. Bovine RSV F DS-Cav1 [36] was expressed and purified analogously. Specifi-
cally, bovine RSV F DS-Cav1 was expressed by transient transfection of Expi293F cells using
293Fectin and purified using IMAC, Strep-Tactin affinity and size-exclusion chromatography.
Ethics statement
All mouse experiments were reviewed and approved by the Animal Care and Use Committee of
the Vaccine Research Center, NIAID, NIH, under animal protocol identification number 13–
454, and all animals were housed and cared for in accordance with local, state, federal, and insti-
tute policies in an American Association for Accreditation of Laboratory Animal Care (AAA-
LAC)-accredited facility at the NIH. The calf experiment was performed under the regulations
of the United Kingdom Home Office Scientific Procedures Act (1986). The study was reviewed
and approved by the Animal and Plant Health Agency (APHA) Ethical Review Committee.
Mouse immunizations
CB6F1/J female hybrid mice used in our study are the first filial offspring of a cross between
BALB/cJ females (C) and C57BL/6J males (B6) (The Jackson Laboratory). These mice were
used in our earlier RSV immunogenicity experiments; provide increased genetic complexity
and flexibility and allow direct comparison to our prior results. Mice at age 10 weeks were
injected with RSV F DS-Cav1-adjuvant mixtures at week zero and week three for homologous
prime-boosts into the semimembranosus muscle of both pelvic limbs with 10 μg of RSV F
DS-Cav1 immunogen with or without adjuvants. All immunizations were given intramuscu-
larly; each animal received in total 100μl of PBS containing 10 μg of RSV F DS-Cav1 immuno-
gen: in 100μl inoculant with 50 μl (50% v/v) mixture of Sigma Adjuvant System (SAS) (Sigma)
for the SAS group; in 100μl inoculant with 50 μg (5 fold w/w) of Poly (I:C) for the Poly (I:C)
group; in 100μl inoculant with 50 μg (5 fold w/w) of Poly (IC:LC) for the Poly (IC:LC) group;
in 100μl inoculant with 20 μg (2 fold w/w) of Monophosphoryl Lipid A for the MPLA group;
in 100μl inoculant with 100 μg (10 fold w/w) of Alum for the Alum group; in 100μl inoculant
with 50 μl (50% v/v) mixture of Sigma Adjuvant System plus 20 ng (0.02% w/v) of Carbopol
for the SAS + Carbopol group; in 100μl inoculant with 50 μl (50% v/v) of AddaVax for the
AddaVax group; in 100μl inoculant with 20 μl (20% v/v) of Adjuplex for the Adjuplex group;
in 100μl inoculant with 20 μg (2 fold w/w) of Monophosphoryl Lipid A plus 100 μg (10 fold w/
w) of Alum for the MPLA + Alum group. Inoculants were formulated within one hour before
immunization followed by mixing immediately prior to injections. A control group with no
adjuvant was also included in the study. No adverse effect from immunization was observed in
any study animal. Sera samples were collected at least three days before immunization, and
two weeks after each immunization or any indicated time points. Animal experiments were
conducted in full compliance with all relevant federal regulations and NIH guidelines. For the
elderly mice study, two groups of seven mice that had been pre-immunized multiple times
Adjuvants for DS-Cav1-stabilized RSV F
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with DS-Cav1: Poly (I:C) formulation were immunized twice with DS-Cav1 formulated with
Alum and SAS + Carbopol after a waiting period of ~83 weeks. As with naïve mice, two injec-
tion sites in the semimembranosus muscle of both pelvic limbs were used for each immuniza-
tion. No adverse effect from immunization was observed. Sera were collected at least three
days before immunization, and at weeks two and weeks five post initial immunization.
Calf immunizations
BRSV seronegative male calves were produced as described previously [36] and vaccinated
intramuscularly with 50 μg of bRSV F DS-Cav1 adjuvant mixtures in a volume of 2 ml on two
occasions 4 weeks apart. Calves were 3 to 6 weeks of age at the time of vaccination. Five calves
were vaccinated with bRSV F DS-Cav1 emulsified with MontanideTM ISA 71 VG (Seppic,
France) in a water in oil emulsion at a ratio of 70:30 adjuvant to aqueous phase, as described
previously [36] and two calves were vaccinated with bRSV F DS-Cav1 plus Carbopol 1:1 v/v
emulsified with MontanideTM ISA 71 VG 1:1 v/v. Calves developed either mild or no swelling
at the injection sites and a transient fever 24 h after vaccination. Sera were collected at one to
two weekly intervals after vaccination.
Viruses and cells for RSV neutralization assays
Viral stocks were prepared and maintained as previously described [37]. Recombinant mKate-
RSV expressing prototypic subtype A (strain A2) F genes and the Katushka fluorescent protein
were constructed as reported by Hotard et al. [38]. HEp-2 cells (ATCC, VA) were maintained
in Eagle’s minimal essential medium containing 10% fetal bovine serum (10% EMEM), supple-
mented with glutamine, penicillin and streptomycin.
RSV neutralization assays
The neutralization antibody was measured by a fluorescence plate reader neutralization assay.
2.4 x 104 HEp-2 cells/well in 30 μl culture medium were seeded in 384-well black optical bot-
tom plate (Nunc1384-well plates, Thermo Scientific, West Palm Beach, FL). When palivizu-
mab (Synagis1) is dosed at a concentration of 15 mg/kg, serum levels at trough are ~40 μg/
ml, which provides protection in infants from severe disease and protection in cotton rats
from RSV infection. In our neutralization assay, ~40 μg/ml of palivizumab yields an EC50 of
100 [10]. Serum samples were diluted in four-fold dilutions starting from 1:10 to 1: 163840, an
equal volume of recombinant mKate-RSV A2 was added and mixed, incubated at 37˚C for one
hour, after incubation, 50 μl mixture of sample and virus was added to cells/well in the
384-well plate, which was incubated at 37˚C for 22–24 hours. After incubation, assay plates
were analyzed for fluorescence intensity in a microplate reader at an excitation wavelength of
588 nm and emission wavelength of 635 nm (SpectraMax Paradigm, Molecular Devices, Sun-
nyvale, CA 94089). EC50 of neutralization of sample was calculated by curve fitting using
GraphPad Prism 6 software (GraphPad Software Inc., San Diego. CA).
Bovine RSV neutralization assays
BRSV microneutralization assay was performed using 500–1,000 TCID50 (50% tissue culture
infectious doses) of bRSV, strain 375 (ATCC VR1339) and BT cells (ATCC CRL1390) [36].
Briefly, immune sera were serially diluted in quadruplicates prior to mixing with 500–1000
TCID50 of bRSV for 1 h at 37˚C in a humidified 5% CO2 atmosphere prior to addition to
monolayers of BT cells seeded the day before at 8000 cells/well. Cells were then incubated for 7
days, fixed with 70% methanol, stained with 1% crystal violet and examined at the microscope
Adjuvants for DS-Cav1-stabilized RSV F
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for syncytia formation and cytopathic effect (CPE). Neutralizing titer was defined as the recip-
rocal of the highest sera dilution at which the infectivity of bRSV was completely neutralized
in 50% of the wells. Infectivity was identified by the presence of CPE and syncytia on day 7,
and the titer was calculated by the Reed- Muench method [39].
Sera binding analysis
A forte´Bio Octet Red384 instrument was used to measure sera recognition of DS-Cav1,
DS-Cav1 antigenic site Ø KO, DS-Cav1 antigenic site II KO, RSV post F and RSV post F site II
KO proteins [40] to probe antigenic site Ø (D25, AM22) and site II (motavizumab) targeting
antibodies. A series of scouting experiments at different sera dilutions, buffer conditions and
sensor tips were performed to minimize non-specific binding. Optimum non-specific binding
was obtained using HIS1K sensor tips and sera dilutions in the range of 1:100–1:300 in PBS
supplemented with 1% BSA. Initial assays using sera from 10 groups of mice that had been
immunized with DS-Cav1: adjuvant formulations as well as the pre-bleed sera with the three
pre-fusion specific and two post fusion specific probes were performed at 30˚C in tilted black
384-well plates (Geiger Bio-One) with agitation set to 1,000 rpm in PBS supplemented with
1% BSA and a well volume of 55 μl. All experiments were performed in duplicate and included
6–10 mice samples per group based on sera availability. DS-Cav1 and DS-Cav1 KO and Post F
KO probes (20 μg/ml) were immobilized for 300s on HIS1K biosensor tips and equilibrated
for 60 s in 1% BSA/PBS prior to measuring association with sera diluted 1:100 in BSA/PBS.
Variability in loading within a row of eight tips did not exceed 0.1 nm for each of these steps.
Parallel correction to subtract systematic baseline drift was carried out by subtracting the mea-
surements recorded for a loaded sensor incubated in PBS + 1% BSA. The association after 300
s was recorded. A similar assay was used to measure sera reactivity for the two groups of pre-
immunized mice at ~85 weeks post immunization as well as the two boosts to DS-Cav1, Post
F, DS-Cav1 site Ø KO, DS-Cav1 site II KO and Post F site II KO probes. Data analysis was per-
formed using Octet and GraphPad Prism 6 software.
Measurement of IgG response by ELISA
Maxisorp plates (Nunc, 96 well) were coated with DS-Cav1 at 1μg/ml in PBS at 4˚C overnight.
Plates were washed and blocked [41] and incubated with serial dilutions of mouse sera from
the 10 different groups, pre-bleed sera from each group was included as a negative control.
Anti-mouse IgG1 or IgG2a-conjugated with horse radish peroxidase were used as secondary
antibodies and 3, 5, 3´5´-tetramethylbenzidine (TMB) was used as the substrate to detect RSV
F specific IgG1 or IgG2a antibody responses. Endpoint titers were calculated as the highest
serum dilution that gave an optical density exceeding five times the background. ELISA was
performed in duplicate and included 6–10 mice samples per group based on sera availability
and endpoint titers were averaged and analyzed using GraphPad Prism 6 software. A similar
assay performed in duplicate, was used to measure IgG response in the two groups of seven
elderly mice at ~85 weeks post immunization as well as the two post boost 1 and post boost 2
time points. Endpoint titers were averaged and analyzed using GraphPad Prism 6 software.
Results
Immunogenicity of RSV F DS-Cav1-adjuvant formulations in mice
DS-Cav1-adjuvant mixtures were used to immunize 10 groups of 10 CB6F1/J mice. For each
group, 10 μg of DS-Cav1 was formulated with nine different adjuvants and injected intramus-
cularly twice at an interval of three weeks (Fig 1A). After two immunizations, in the week five
Adjuvants for DS-Cav1-stabilized RSV F
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sera, significantly higher EC50 neutralization titers were observed in mice immunized with
DS-Cav1 adjuvanted with Alum, TLR3 agonists Poly (I:C), Poly (IC:LC), TLR4 agonists SAS,
SAS + Carbopol, a polyanionic high molecular weight acrylic acid, and Adjuplex, an adjuvant
based on purified lecithin and carbomer homopolymer (with geometric mean titers of 4850,
3687, 3658, 7108, 19006, 5092, respectively) than for DS-Cav1 adjuvanted with TLR4 agonist
MPLA, Alum plus MPLA and AddaVax (with geometric mean titers of 2129, 1251, and 1264,
respectively, Fig 1B). Neutralization titers for the control unadjuvanted DS-Cav1 were below
the protective threshold [10] and at the level of detection (Fig 1B). Titers for DS-Cav1 adju-
vanted with a combination of SAS, a TLR4 agonist and Carbopol were 15-fold higher than that
observed for the lowest neutralizing group represented by DS-Cav1 adjuvanted with Alum
plus MPLA (p< 0.0009) and four to five-fold higher than DS-Cav1 adjuvanted with Alum
(p = 0.0136) or the TLR3 agonists Poly (I:C) (p = 0.0028), or Poly (IC:LC) (p = 0.0025), respec-
tively. Interestingly, the TLR4 agonist MPLA by itself or when formulated with Alum did not
help elicit high neutralization titers. Conversely, the TLR4 agonist present as a component in
SAS and SAS + Carbopol adjuvants helped elicit the highest immune response among the nine
adjuvant groups.
RSV F DS-Cav1-adjuvant formulations direct the neutralizing response
to antigenic sitesØ, II
To understand the higher neutralization titers and delineate the role of the adjuvants to immu-
nogenicity, we investigated whether sera reactivity was directed towards pre-fusion specific
antigenic site Ø on DS-Cav1 or antigenic site II that is present in both pre-and post-fusion
forms of RSV F protein (Fig 2A). We explored site-specific immune response with the aid of a)
DS-Cav1 probes with KO mutations in antigenic site Ø, and b) DS-Cav1 and Post F probes
with KO mutations in antigenic site II [12, 40]. We initially measured binding of week 5 sera
to DS-Cav1, Post F, DS-Cav1 site Ø KO, DS-Cav1 site II KO and Post F site II KO probes
using BioLayer Interferometry. Sera reactivity for five groups corresponding to Poly (I:C),
Poly (IC:LC), SAS, SAS + Carbopol and Adjuplex showed the greatest response to DS-Cav1,
followed by AddaVax and Alum. Sera corresponding to MPLA, and MPLA plus Alum exhib-
ited the lowest binding response (Fig 2B). Furthermore, sera from all groups exhibited reduced
binding to DS-Cav1 site Ø KO (Fig 2B). The pre-fusion specific site Ø KO probe bound signifi-
cantly less to sera from Poly (I:C), Poly (IC:LC), SAS, SAS + Carbopol, and Adjuplex adjuvant
groups relative to DS-Cav1 (p = 0.0006, 0.0040, 0.0043,0.0040 and 0.0019 respectively), demon-
strating that these five adjuvants could facilitate a robust response to antigenic site Ø. In con-
trast, no significant difference was observed in sera from the Alum, MPLA, MPLA + Alum
and AddaVax groups (Fig 2B), indicating that these adjuvants were unable to enhance the
immune response to antigenic site Ø. Examining the sera response to antigenic sites as probed
by DS-Cav1 site II knockout and Post F site II knockout probes, further demonstrated that the
neutralizing antibody response was focused to pre-fusion specific antigenic sites displayed on
RSV F.
RSV F DS-Cav1-adjuvant formulations elicit antibodies of different IgG
subclasses
We next analyzed sera for the quality of humoral response induced by the different adjuvant
formulations and found that they elicit different IgG subclass response patterns (Fig 3). For-
mulations with MPLA, Alum plus MPLA, AddaVax and Adjuplex induced an IgG1 response
with no detectable IgG2a response. On the other hand, DS-Cav1 formulated with Alum
induced a primarily IgG1 response and DS-Cav1 formulations with SAS, SAS + Carbopol,
Adjuvants for DS-Cav1-stabilized RSV F
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Poly (I:C) and Poly (IC: LC) induced both an IgG1 and IgG2a response. Unadjuvanted
DS-Cav1 induced a marginal IgG1 response and no detectable IgG2a response. The IgG sub-
class response pattern appeared to be determined not only by the properties of the adjuvant
but also by the protein adjuvant formulation. The IgG2a and IgG1 subclass responses reflect
the respective T helper 1 cell (Th1) and T helper 2 cell (Th2) biased immune response patterns
in mice [42]. The slight IgG1 dominant response elicited by unadjuvanted DS-Cav1 is likely
due to stimulation of Th2 biased response in mice [41, 43]. Although MPLA is known to aug-
ment a Th1 biased response the MPLA and MPLA + Alum adjuvant formulations were not
sufficient to influence the IgG response towards a Th1 phenotype nor were Adjuplex and
AddaVax sufficient to influence the IgG response towards the expected balanced Th1/Th2
Fig 1. Adjuvants augment DS-Cav1 response in mice. (A) RSV F (pre-F) DS-Cav1 formulated with nine different adjuvants was used to
immunize mice at an interval of 3 weeks and (B) neutralization titers for all nine adjuvanted plus the control unadjuvanted groups are
shown. Scatter plots show the geometric mean (numerical value below), each group included 10 mice. The palivizumab protective
threshold is indicated by a dotted line [10] and p values for SAS + Carbopol/DS-Cav1 versus the other eight adjuvant formulations as
assessed by two-tailed Mann-Whitney test and adjusted for multiple comparisons using the Holm-Bonferroni method; p = > 0.05 (ns);
p < 0.05 (*); p < 0.01 (**); p < 0.001 (***) are shown. All adjuvanted groups show p < 0.0001 when compared to the no adjuvant group.
Associated raw data is reported in S1 Table.
https://doi.org/10.1371/journal.pone.0186854.g001
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response [19, 44]. As expected, the Alum adjuvant formulations stimulated primarily the
expected IgG1 with some IgG2a response for Alum alone. The IgG1 to IgG2a ratio indicated a
significantly greater Th2-biased response for DS-Cav1 adjuvanted with Alum, MPLA, Adju-
plex (p< 0.001) than for Poly (I:C), Poly (IC:LC), SAS and SAS + Carbopol which gave a bal-
anced IgG1 to IgG2a response (Fig 3A and 3B).
Effect of RSV F DS-Cav1-adjuvant formulations on neutralization titers in
elderly mice
DS-Cav1-adjuvant mixtures were used to immunize two groups of elderly CB6F1/J mice. Each
group of elderly mice had been pre-immunized prior to 12 weeks of age with DS-Cav1-Poly (I:
C) formulation and were administered two final DS-Cav1 boosts at week 90 and 93 respec-
tively formulated with Alum or SAS + Carbopol after a waiting period of ~85 weeks (Fig 4A)
and their immune responses were assessed (Fig 4B). Reciprocal EC50 neutralization titers had
waned during the ~85 week interval period. However, a single boost with DS-Cav1 with Alum
formulation increased the neutralization titers to the week five level (p = 0.0313) and titers did
not increase after a second immunization at week 93. Interestingly, when DS-Cav1 adjuvanted
with SAS + Carbopol was used to boost the elderly mice, neutralization titers increased from
the waned response (p =>0.05), but remained lower than the initial response observed in
young mice. Thus, in elderly mice that experienced multiple RSV immunizations as young
mice, but still had modest levels of serum-neutralizing activity, boosting the response with
alum as an adjuvant could effectively achieve above threshold levels of protective immunity.
RSV F DS-Cav1-adjuvant formulations direct the antibody response to
antigenic sitesØ and II in elderly mice
We further investigated whether sera reactivity in pre-immunized elderly mice was directed
towards pre-fusion specific antigenic site Ø on DS-Cav1 or antigenic site II that is present in
both pre- and post-fusion forms of the RSV F protein (Fig 5). As in the case of young mice, we
explored site-specific immune responses with the aid of a) DS-Cav1 probes with KO mutations
in antigenic site Ø and b) DS-Cav1 and Post F probes with KO mutations in antigenic site II
[12, 40]. We measured binding of sera from ~85 weeks post immunization as well as the two
boosts to DS-Cav1, Post F, DS-Cav1 site Ø KO, DS-Cav1 site II KO and Post F site II KO
probes using BLI. Sera responses to the pre- and post- F probes exhibited a profile nearly iden-
tical to the neutralization titers (Figs 4 and 5) and we also observed a significant fraction of
response (p =<0.05) targeted to antigenic site Ø.
RSV F DS-Cav1-adjuvant formulations modulate antibody responses in
elderly mice
We also analyzed sera from the elderly mice immunizations for the quality of humoral
response induced by Alum and SAS + Carbopol adjuvant formulations (Fig 6A and 6B). Inter-
estingly, both groups of DS-Cav1 adjuvant formulations elicited a balanced IgG1 and IgG2a
subclass response pattern. As expected, elderly mice immunized with DS-Cav1 adjuvanted
Fig 2. Sera from mice immunized with DS-Cav1-adjuvant mixtures exhibit differential antibody responses to sitesØ and II KO probes. (A) Unique
and shared antigenic sites on pre-and post RSV F. Antigenic siteØ, a major target of neutralizing antibodies (e.g. D25) and antigenic site II present in both
conformations of RSV F are shown on the pre-F and post-F structures. (B) Recognition of pre-fusion forms of RSV F (DS-Cav1), DS-Cav1 siteØ KO and site
II KO probes by week 5 sera for the nine DS-Cav1 adjuvant groups. Scatter plots show the geometric mean. Pre-bleed sera from 10 mice were used as
control. p values for DS-Cav1 versus DS-Cav1 siteØ, site II KO probes and Post-F probes as assessed by two-tailed Mann-Whitney test; p = > 0.05 (ns);
p < 0.05 (*); p < 0.01 (**); p < 0.001 (***) are shown. Associated raw data is reported in S2 Table.
https://doi.org/10.1371/journal.pone.0186854.g002
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with SAS + Carbopol, retained the IgG subclass response pattern observed in young mice (Figs
Fig 3. DS-Cav1-adjuvant formulations elicit antibodies of different IgG subclass in immunized mice. (A) Sera from naïve mice primed
and boosted with DS-Cav1 adjuvant mixtures were assayed by ELISA for their RSV F DS-Cav1 specific IgG1 and IgG2a antibody responses.
Scatter plots show the geometric mean, closed circles and open triangles represent IgG1 and IgG2a antibody titers, respectively. (B) The
ratios of IgG1 to IgG2a for each animal in the adjuvanted groups were calculated from the upper panel. p-values were determined using a two-
tailed Mann-Whitney test and were adjusted for multiple comparisons using the Holm-Bonferroni method, p < 0.001 (***). Associated raw
data is listed in S3 Table.
https://doi.org/10.1371/journal.pone.0186854.g003
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3A and 6A). On the other hand, elderly mice immunized with alum-adjuvanted DS-Cav1 did
not elicit a strongly IgG1 skewed response as observed in young mice, but instead elicited a
more balanced IgG2a/IgG1 response. The IgG1 to IgG2a ratios of boost 1 and boost 2 in the
SAS + Carbopol and Alum groups were not significantly different from their corresponding
time point at 85 weeks p.i. (p =>0.05). Thus, the IgG subclass response pattern appeared to be
determined by the priming immunization as the DS-Cav1-Poly (I:C) adjuvant formulation
induced a balanced IgG1/IgG2a response in naïve mice.
Fig 4. Adjuvanted DS-Cav1 can augment RSV-neutralization titers in elderly mice. (A) Pre-immunized elderly mice (DS-Cav1
adjuvanted with Poly (I:C), ~85 weeks wait) were administered DS-Cav1 formulated with Alum or SAS + Carbopol and the immune
response for all mice assessed. (B) Neutralization titers for each group of seven elderly mice are shown. Scatter plots show the
geometric mean (numerical value below), the palivizumab protective threshold is indicated by a dotted line [10]. p values were
determined by two-tailed Wilcoxon matched-pairs signed rank test, p = >0.05 (ns); p < 0.05 (*). Associated raw data is reported in S4
Table.
https://doi.org/10.1371/journal.pone.0186854.g004
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Fig 5. Boost by adjuvanted RSV F DS-Cav1 can focus the RSV immune response to antigenic siteØ and II in elderly mice.
Pre-immunized elderly mice (~85 weeks wait) were administered (A) DS-Cav1 formulated with SAS + Carbopol or (B) DS-Cav1
formulated with Alum and recognition of DS-Cav1, DS-Cav1 siteØ KO, DS-Cav1 site II KO, Post F and Post F site II KO probes by
sera for all immunized mice assessed. Scatter plots show the geometric mean. p values were determined by two-tailed Wilcoxon
matched-pairs signed rank test, p = >0.05 (ns); p < 0.05 (*). Associated raw data is reported in S5 Table.
https://doi.org/10.1371/journal.pone.0186854.g005
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Fig 6. Prime-boost vaccination with different adjuvant formulations induced a balanced Th1/Th2 IgG
response in elderly mice. (A) Pre-immunized elderly mice (~85 weeks wait) were administered DS-Cav1
formulated with SAS + Carbopol or Alum. Sera were assayed by ELISA for their DS-Cav1 specific IgG1 and
IgG2a antibody responses. Closed circles and open triangles represent IgG1 and IgG2a antibody titers,
respectively. (B) The ratios of IgG1 to IgG2a for each animal in the groups were calculated from the upper
panel. p values were determined by two-tailed Wilcoxon matched-pairs signed rank test, p = >0.05 (ns).
Associated raw data is listed in S6 Table.
https://doi.org/10.1371/journal.pone.0186854.g006
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Effect of adjuvant formulations on neutralization titers of bovine RSV F
DS-Cav1 in mice and cattle
We tested whether the very high EC50 titers observed with DS-Cav1 adjuvanted SAS + Carbo-
pol in mice were also higher with pre-F stabilized bovine RSV F in mice and cattle. Bovine
DS-Cav1 adjuvanted with Poly (I:C) and SAS + Carbopol mixtures were used to immunize
two groups of 10 CB6F1/J mice. After two immunizations, in the week five sera, significantly
higher reciprocal EC50 neutralization titers were observed in the SAS + Carbopol group as
compared to the Poly (I:C) group (with geometric mean titers of 50784 and 6879, respectively,
and a p value = 0.0019, Fig 7). We next immunized cattle with bovine DS-Cav1 adjuvanted
with the analogous water in oil adjuvant ISA 71 VG and ISA 71 VG-Carbopol formulations.
Rather surprisingly, no significant difference was observed in neutralization titers from the
ISA 71 VG, and ISA 71 VG plus Carbopol groups indicating this combination of adjuvants did
not significantly enhance the immune response in cattle (Fig 7).
Discussion
Vaccine formulations that include antigens and agonists of the immune system and antigen
presenting cells that selectively present a target antigen to the immune system can greatly
influence the immunity elicited from vaccination. Adjuvants may influence the type of
immune profile as well as the breadth of neutralizing antibodies [45] or the persistence of the
protective response. One of the major goals of vaccination against RSV is to induce immunity
in a wide range of age groups from neonates to the elderly. In the elderly population who have
experienced repeated RSV infections throughout life, and have some pre-existing immunity,
boosting the response to neutralization-sensitive epitopes could achieve threshold levels of
protective immunity. This may require formulations of a RSV vaccine with different adjuvants.
We undertook a comparative study of adjuvants on a single immunogen RSV F DS-Cav1 in
naïve and elderly CB6F1/J mice. In our study with naïve mice significantly higher EC50 neu-
tralization titers were observed in six groups of mice immunized with DS-Cav1: Alum, SAS,
SAS + Carbopol, Adjuplex, Poly (I:C) and Poly (IC:LC) than for DS-Cav1 adjuvanted with
TLR4 agonist MPLA, Alum plus MPLA and AddaVax, whereas unadjuvanted DS-Cav1 titers
were below the protective threshold (Fig 1). Alum surprisingly exhibited stronger adjuvant
effects on the magnitude of antibody response than MPLA or Alum + MPLA when formulated
with DS-Cav1, even though ASO4 (Alum plus MPLA formulation) has a synergistic effect
when adjuvanted with HPV virus-like particles [46]. Thus, immunogenicity may be influenced
not just by the properties and concentration or dose of the adjuvant [47] but also by the combi-
nation of immunogen and adjuvant. It is not known whether there is a specific property of
Alum that improves the response or whether TLR4 agonists like MPLA in some way interfere
with the responses to RSV F.
Titers of pre-fusion-F specific antibodies have been shown to correlate with the magnitude
of RSV neutralizing activity in human sera [40]. We therefore interrogated DS-Cav1- immune
sera using three antigenic site-specific probes (Fig 2B) and found that as with human sera,
highly neutralizing sera from Poly (I:C), Poly (IC:LC), SAS and SAS + Carbopol groups elicit
polyclonal response primarily to site Ø and to a much lesser extent to site II presented in the
pre-fusion state of RSV F.
IgG2a and IgG1 subclass responses, reflect respective T helper 1 (Th1) and T helper 2 cell
(Th2)-biased immune response patterns in mice [42]. Interestingly, SAS, SAS + Carbopol,
Poly (I:C) and Poly (IC:LC) groups induced a balanced Th1/Th2 IgG response, whereas Alum,
MPLA, Alum plus MPLA, Adjuplex and Addavax induced a predominantly Th2-biased IgG1
response. Adjuvant groups with high neutralization titers against RSV exhibited a balanced
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Th1/Th2 response. High titer neutralizing antibodies have been reported with a balanced Th1/
Th2 response when mice were immunized with reconstituted virosomes produced from RSV
envelopes containing a lipopeptide adjuvant [48]. In contrast, to the Th2-biased response
induced by DS-Cav1 with Adjuplex, a balanced Th1/Th2 response was obtained when mice
Fig 7. Bovine pre-fusion RSV F response in mice and cattle. Pre-F bovine RSV F DS-Cav1 formulated
with two adjuvants was used to immunize mice and calves and resulted in high neutralization titers. Mice were
administered DS-Cav1 formulated with Poly(I:C) and SAS + Carbopol, whereas, cattle were administered with
an analogous water in oil emulsion, ISA 71 VG-DS-Cav1 formulation and ISA 71 VG + Carbopol–DS-Cav1
formulation. Scatter plots show the geometric mean (numerical value below), each group included 10 mice
and 2–5 calves. Level of detection is indicated by a dotted line; and p value for SAS + Carbopol/DS-Cav1
versus the Poly (I:C) formulations in mice as assessed by two-tailed Mann-Whitney test is shown; p = 0.0019.
(Control groups without Carbopol were reported previously in ref. [36]).
https://doi.org/10.1371/journal.pone.0186854.g007
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were immunized with influenza HA protein formulated with Adjuplex [19]. In elderly mice
with some pre-existing immunity, boosting the response with Alum as an adjuvant could
achieve high levels of protective immunity whereas with SAS + Carbopol as an adjuvant, more
than one immunization was necessary to achieve a similar level of neutralization. In contrast,
Alum adjuvant with RSV F protein in elderly BALB/c mice also conferred protection (neutral-
izing anti-RSV F antibody titers) albeit the protection was sub-optimal compared to that seen
in young mice [49]. Interestingly, in the Alum group for elderly mice, the IgG1/IgG2a response
was determined by the priming immunization of naïve mice as the DS-Cav1-Poly (I:C) prime
boost regimen induced a balanced IgG1/IgG2a pattern. Thus, our results indicate that the RSV
F vaccine immune response in mice is not just influenced by the properties and concentration
or dose of the adjuvant [47] but can be augmented by combinations of antigen and adjuvant
and adjuvants that enable a Th1/Th2 –balanced response result in higher RSV neutralizing
activity in mice. Overall, our data support the fact that adjuvants play less of a role in determin-
ing responses following a boost in pre-immune animals than they do in the inductive event fol-
lowing a primary immunization. While the addition of Carbopol to the oil-in-water adjuvant
SAS enhanced the antibody response in mice, the addition of Carbopol to the water-in-oil
adjuvant ISA 71 VG did not appear to enhance the antibody response in calves. Overall, our
results suggest that the particulars of different adjuvants may be species specific. Furthermore,
the role of adjuvants in the context of RSV immunization and the legacy of formalin-inacti-
vated RSV (FI-RSV) vaccine-enhanced illness should be considered. There are two major
immunological patterns associated with the formalin-inactivated RSV (FI-RSV) vaccine-
enhanced illness. One was poor functional neutralizing antibody (NT) activity despite induc-
tion of significant binding antibody. This is thought to contribute to immune complex deposi-
tion in small airways that were documented in the children who died from the FI-RSV
enhanced respiratory disease (ERD) [50]. The second pattern was a Th2-biased CD4 T cell
response associated with eosinophilia and neutrophilic alveolitis [51]. Although it is possible
that if sufficient NT activity is induced and the specificity of the response is corrected that
controlling the T cell response patterns with adjuvants may make it possible to test protein-
based vaccines again in RSV-naïve neonates, it will be a difficult regulatory hurdle. If the dose
of a stabilized pre-F antigen is reduced to very low levels to induce a subprotective antibody
response, it is possible to simulate the pattern of lung inflammation seen with full doses of
less effective vaccines [52]. Therefore, just using the correct conformation of a vaccine antigen
and redirecting antibody to neutralization-sensitive sites may not be sufficient, even with
Th1-biased adjuvants, to prevent a pathogenic inflammatory response to breakthrough infec-
tion. For the pre-F vaccine antigen delivered as protein the ultimate target populations are
pregnant women, the elderly, and potentially older children. All these groups will have been
primed by natural infection, so the role of adjuvant is primarily to increase the magnitude of
the response based on the established precursor T cell and B cell populations. For pregnant
women, vaccination should avoid excessive Th1-biased responses for safety concerns related
to the pregnancy. If adjuvants are needed to boost antibody responses to protective levels in
adults, alum-based formulations may have an acceptable safety and immunological profile for
use in pregnancy. In the elderly or older children, the most potent, tolerable adjuvant should
be chosen based on results from early phase clinical trials.
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